Sigyn Therapeutics Relocates HQ to Beverly Hills
Ticker: SIGY · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1642159
| Field | Detail |
|---|---|
| Company | Sigyn Therapeutics, Inc. (SIGY) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative-change, address-change
TL;DR
**Sigyn Therapeutics moved its main office to Beverly Hills, CA.**
AI Summary
Sigyn Therapeutics, Inc. filed an 8-K on January 8, 2024, to update its principal executive offices. The company's new business address is 9190 W Olympic Blvd # 263, Beverly Hills, CA 90212, changing from its previous San Diego location. This matters to investors because a change in headquarters can sometimes signal strategic shifts, cost-cutting measures, or a move closer to key partners or talent, potentially impacting future operational efficiency and investor confidence.
Why It Matters
A change in headquarters can signal operational shifts or strategic realignment, potentially affecting investor perception and future business trajectory.
Risk Assessment
Risk Level: low — This filing primarily reports an administrative change of address, which typically carries minimal direct financial risk.
Analyst Insight
Investors should note the administrative change but recognize that this filing alone does not provide material financial or operational insights. Further investigation into the reasons behind the move might be warranted if other strategic shifts are observed.
Key Players & Entities
- Sigyn Therapeutics, Inc. (company) — the registrant filing the 8-K
- 9190 W Olympic Blvd # 263, Beverly Hills, CA 90212 (address) — new principal executive offices
- 2468 Historic Decatur Road, Suite 140, San Diego, CA 92106 (address) — prior principal executive offices
- January 4, 2024 (date) — date of earliest event reported
- January 8, 2024 (date) — filing date of the 8-K
FAQ
What is the primary purpose of Sigyn Therapeutics, Inc.'s 8-K filing dated January 8, 2024?
The primary purpose of the 8-K filing is to report a change in the company's principal executive offices, as indicated by the 'Date of earliest event reported: January 4, 2024' and the updated address information.
What is Sigyn Therapeutics, Inc.'s new principal executive office address?
Sigyn Therapeutics, Inc.'s new principal executive office address is 9190 W Olympic Blvd # 263, Beverly Hills, California 90212, as stated in the filing.
What was Sigyn Therapeutics, Inc.'s previous principal executive office address?
The company's previous principal executive office address was 2468 Historic Decatur Road, Suite 140, San Diego, CA 92106, according to the 'Prior address and phone number' section of the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 4, 2024, as specified by 'Date of report (Date of earliest event reported): January 4, 2024'.
What is the business phone number for Sigyn Therapeutics, Inc. at its new address?
The business phone number for Sigyn Therapeutics, Inc. at its new address is 619-368-2000, as listed under 'Registrant’s telephone number, including area code'.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-08 14:34:59
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 37KB
- 0001493152-24-001690.txt ( ) — 250KB
- sigy-20240104.xsd (EX-101.SCH) — 3KB
- sigy-20240104_lab.xml (EX-101.LAB) — 33KB
- sigy-20240104_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO